Ischemic stroke is a common neurological disease. Currently, there are no Food and Drug Administration-approved drugs that can maximize the improvement in ischemic stroke-induced nerve damage. Hence, treating ischemic stroke remains a clinical challenge. Ferroptosis has been increasingly studied in recent years, and it is closely related to the pathophysiological process of ischemic stroke. Iron overload, reactive oxygen species accumulation, lipid peroxidation, and glutamate accumulation associated with ferroptosis are all present in ischemic stroke. This article focuses on describing the relationship between ferroptosis and ischemic stroke and summarizes the relevant substances that ameliorate ischemic stroke-induced neurological damage by inhibiting ferroptosis. Finally, the problems in the treatment of ischemic stroke targeting ferroptosis are discussed, hoping to provide a new direction for its treatment.

缺血性脑卒中是一种常见的神经系统疾病。目前，尚无美国食品药品监督管理局批准的药物能够最大限度地改善缺血性中风引起的神经损伤。因此，治疗缺血性中风仍然是临床挑战。近年来铁死亡的研究日益增多，其与缺血性脑卒中的病理生理过程密切相关。铁过载、活性氧积累、脂质过氧化以及与铁死亡相关的谷氨酸积累都存在于缺血性中风中。本文重点描述铁死亡与缺血性中风之间的关系，并总结通过抑制铁死亡来改善缺血性中风引起的神经损伤的相关物质。最后对缺血性脑卒中靶向铁死亡治疗中存在的问题进行了探讨，希望为其治疗提供新的方向。